• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ACNV
Share

Accelera Innovations, Inc Stocks

$ 0Last Updated 30.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

Critical

Recommendation

Sell

Market Cap

$ 8141

$ 0
Key Takeaways

Risk factor

Critical default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Accelera Innovations, Inc. functions as a healthcare services provider, primarily engaged in developing Internet-based software solutions across the United States. Its core offering, Accelera Technology, is an online platform that aims to improve the efficiency and capabilities of healthcare services by making vital clinical health information accessible to consumers. In addition to its software, the company offers key support services such as billing, practice management, and administrative assistance to medical professionals and clinicians. It also provides home health services to patients in the Chicago area. Founded in 2008, the company changed its name from Accelerated Acquisitions IV, Inc. to Accelera Innovations, Inc. in October 2011 and is based in Colorado Springs, Colorado.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.08.2026 16:01

Small caps last week: Cathie Wood’s Scribe bet, deals to acquire Forte Bio and CBIZ

01.08.2026 13:01

Apple's Short-Lived Triumph, Non-Banks Battle for Colombia, and a Dinosaur Worth Millions of Dollars

01.08.2026 04:17

Not a White Knight: How the “Savior” of “AI-Nostradamus” Makes Money by Sensing Trouble

01.08.2026 03:08

Trump Ordered New Strikes Against Iran — WSJ

01.08.2026 02:07

The Nasdaq Composite had its worst July in 20 years due to a plunge in chipmaker stocks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026